102 related articles for article (PubMed ID: 16939634)
1. Ambrisentan, a non-peptide endothelin receptor antagonist.
Vatter H; Seifert V
Cardiovasc Drug Rev; 2006; 24(1):63-76. PubMed ID: 16939634
[TBL] [Abstract][Full Text] [Related]
2. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of ambrisentan.
Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
5. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
6. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
7. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Peacock AJ; Zamboni W; Vizza CD
Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
[TBL] [Abstract][Full Text] [Related]
9. Ambrisentan.
Newman JH; Kar S; Kirkpatrick P
Nat Rev Drug Discov; 2007 Sep; 6(9):697-8. PubMed ID: 17907344
[No Abstract] [Full Text] [Related]
10. Ambrisentan (Myogen).
Billman GE
Curr Opin Investig Drugs; 2002 Oct; 3(10):1483-6. PubMed ID: 12431023
[TBL] [Abstract][Full Text] [Related]
11. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, bosentan, in experimental renal ischemia reperfusion injury.
Kazimoglu H; Uysal E; Dokur M; Gurer AO; Batcioglu K; Uyumlu BA; Petekkaya E; Karadag M
Bratisl Lek Listy; 2020; 121(8):547-553. PubMed ID: 32726116
[TBL] [Abstract][Full Text] [Related]
13. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Nathan SD; Wells AU; Collard HR; Costabel U; Richeldi L; de Andrade J; Khalil N; Morrison LD; Lederer DJ; Shao L; Li X; Pedersen PS; Montgomery AB; Chien JW; O'Riordan TG;
Ann Intern Med; 2013 May; 158(9):641-9. PubMed ID: 23648946
[TBL] [Abstract][Full Text] [Related]
14. Effects of ambrisentan in a patient affected by combined pulmonary fibrosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular findings.
Roccia F; Campolo B; Gallelli L; Spaccarotella C; Mongiardo A; Falcone D; Savino R; Pelaia G; Indolfi C; Maselli R
Clin Drug Investig; 2013 Jun; 33(6):451-7. PubMed ID: 23605508
[TBL] [Abstract][Full Text] [Related]
15. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan (Letairis) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2007 Oct; 49(1272):87-8. PubMed ID: 17938611
[No Abstract] [Full Text] [Related]
17. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.
Muthuraman A; Nafisa K; Sowmya MS; Arpitha BM; Choedon N; Sandy CD; Rishitha N; Johurul I
Life Sci; 2019 Apr; 222():133-139. PubMed ID: 30844374
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor antagonists in pulmonary arterial hypertension.
Dupuis J; Hoeper MM
Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists.
Xia J; Song J; Zhen L; Zhang X; Lei X; Zheng L; Wang Q; Sun H
Bioorg Med Chem Lett; 2011 Jul; 21(13):3894-7. PubMed ID: 21652209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]